EGFR

16 registered clinical trials studyying EGFR — 9 currently recruiting.

Status	Trial	Sponsor	Phase
Recruiting	A Phase 1 Study of EPI-326 in EGFR-mutant NSCLC and HNSCC NCT07462377	EpiBiologics	Phase 1
Recruiting	A Study to Assess the Efficacy and Safety of Zipalertinib Versus Placebo for Adjuvant Treatment in Participant NCT07128199	Taiho Oncology, Inc.	Phase 3
Recruiting	Trilaciclib in Patients Receiving Sacituzumab Tirumotecan for EGFR-mutated, Advanced Non-Small Cell Lung Cance NCT06992739	The First Affiliated Hospital of Xiamen University	Phase 2
Active Not Recruiting	The HER Project: HRD in EGFR-mutated NSCLC NCT07303218	IRCCS San Raffaele	—
Not Yet Recruiting	Primary Tumor Resection Plus Osimertinib in Advanced EGFR-mutant Non-small Cell Lung Cancer NCT07177092	Jianxing He	Phase 2
Recruiting	Sequential Chemotherapy With Befotertinib in Non-Small Cell Lung Cancer (NSCLC) Patients With Resistance to Th NCT07181499	Betta Pharmaceuticals Co., Ltd.	Phase 2
Recruiting	Safety and Preliminary Efficacy of VIR-5525 and VIR-5525 + Pembrolizumab in Participants With Locally Advanced NCT06960395	Vir Biotechnology, Inc.	Phase 1
Recruiting	Kidney-protective Intervention With Salt Substitute After Kidney Tumor Surgery NCT07062952	Jinling Hospital, China	N/A
Recruiting	Firmonertinib Versus Platinum Based Chemotherapy as First-line Treatment for NSCLC With EGFR PACC or EGFR l861 NCT06956001	Allist Pharmaceuticals, Inc.	Phase 3
Recruiting	Neoadjuvant Befotertinib Combined Bevacizumab or Platinum-based Double Chemotherapy for Resectable Locally-adv NCT06755684	Peng Zhang	Phase 2
Unknown	Development of a Fluorescent Visualization System for Non-visible Lung Cancer Nodules NCT06101394	University of Turin, Italy	Phase 2
Active Not Recruiting	A Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of TT125-802 in Subjects With Adva NCT06403436	TOLREMO therapeutics AG	Phase 1
Unknown	Almonertinib Plus Metronomic Oral Vinorelbine NCT05663177	Fujian Cancer Hospital	—
Active Not Recruiting	Real-Time Monitoring of Symptoms in Lung Cancer Patients Receiving Oral Targeted Therapies NCT05370469	University of Virginia	N/A
Unknown	To Evaluate the Efficacy and Safety of Gefitinib in Adjuvant Chemotherapy for Lung Adenocarcinoma NCT03656393	Shenzhen People's Hospital	Phase 3
Completed	Treatment With BIBW 2992, Irreversible Inhibitor of EGFR and HER-2 in Non-small Cell Lung Cancer NCT01542437	Instituto Nacional de Cancerologia de Mexico	Phase 2